Semaglutide Alleviates Ovary Inflammation via the AMPK/SIRT1/NF‑κB Signaling Pathway in Polycystic Ovary Syndrome Mice DOI Creative Commons
Mei Liu,

Sili Guo,

Xiaohan Li

et al.

Drug Design Development and Therapy, Journal Year: 2024, Volume and Issue: Volume 18, P. 3925 - 3938

Published: Sept. 1, 2024

GLP-1 receptor agonists (GLP-1 RA) have been proven to treat several metabolic diseases; however, the effects of RA on polycystic ovary syndrome (PCOS) remain unclear. Here, we aimed investigate whether semaglutide, a novel RA, could alleviate ovarian inflammation in PCOS mice.

Language: Английский

The interplay of gut microbiota, obesity, and depression: insights and interventions DOI Creative Commons
Iryna Halabitska, Pavlo Petakh, Iryna Kamyshna

et al.

Cellular and Molecular Life Sciences, Journal Year: 2024, Volume and Issue: 81(1)

Published: Oct. 30, 2024

Language: Английский

Citations

9
Gut Microbiota in Diabetic-Linked Polycystic Ovarian Syndrome: Mechanisms and Therapeutic Insights DOI
Prachi Mehta, Dipankar Saha,

Abinash Das

et al.

Tissue and Cell, Journal Year: 2025, Volume and Issue: unknown, P. 102870 - 102870

Published: March 1, 2025

Language: Английский

Citations

0
Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review DOI Open Access

Krzysztof Gofron,

Andrzej Wasilewski, Sylwia Małgorzewicz

et al.

Nutrients, Journal Year: 2025, Volume and Issue: 17(8), P. 1303 - 1303

Published: April 9, 2025

Background: GLP-1 analogues are a relatively new class of medications that form the cornerstone diabetes treatment. They possess invaluable glucose-lowering properties without hypoglycemic effects as well strong cardioprotective effects. The gut microbiome has become focus numerous studies, demonstrating its influence not only on but also overall well-being entire body. However, analogs microbiota remain uncertain. Scope review: Our systematic review (based PRISMA guidelines) aimed to gather knowledge analogue composition, richness, and abundance in both animal human models. Conclusions: Thirty-eight studies were included this review. have demonstrated notable impact diversity microbiota. We can conclude, following obtained research results our study, liraglutide promotes growth beneficial genera relevant for metabolic functions. Exenatide exendin-4 administration showed various composition studies. In models, it increased associated with improved metabolism; however, linked better functions escalated inflammation increased. Following dulaglutide administration, increases Bacteroides, Akkermansia, Ruminococcus, connected an model, significant. Finally, varied after semaglutide treatment, which A. muciniphila, known positive functions, increased; microbial decreased. Semaglutide treatment provided indicating many confounding factors semaglutide’s Results due dissimilarities studied populations duration Further is essential confirm these findings recognize their implications clinical outcomes patients.

Language: Английский

Citations

0
Unraveling the Connection between PCOS and renal Complications: Current insights and Future Directions DOI

Haoyu Peng,

Junyi Ren, Yang Zhao

et al.

Diabetes Research and Clinical Practice, Journal Year: 2025, Volume and Issue: 224, P. 112235 - 112235

Published: May 5, 2025

Language: Английский

Citations

0
Semaglutide Alleviates Ovary Inflammation via the AMPK/SIRT1/NF‑κB Signaling Pathway in Polycystic Ovary Syndrome Mice DOI Creative Commons
Mei Liu,

Sili Guo,

Xiaohan Li

et al.

Drug Design Development and Therapy, Journal Year: 2024, Volume and Issue: Volume 18, P. 3925 - 3938

Published: Sept. 1, 2024

GLP-1 receptor agonists (GLP-1 RA) have been proven to treat several metabolic diseases; however, the effects of RA on polycystic ovary syndrome (PCOS) remain unclear. Here, we aimed investigate whether semaglutide, a novel RA, could alleviate ovarian inflammation in PCOS mice.

Language: Английский

Citations

3